TRISTAN REED: Open Payments
NPI 1942657945 · AKRON, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,810 in 139 payments from 13 companies in 2025. Trend: 2023 $402 · 2024 $553 · 2025 $2,810
Food & beverage: $2,733Education: $77
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 24 | $605 |
| Alkermes, Inc. | 24 | $384 |
| Janssen Pharmaceuticals, Inc | 13 | $359 |
| Otsuka America Pharmaceutical, Inc. | 11 | $329 |
| ABBVIE INC. | 21 | $236 |
| Neurocrine BioSciences, Inc. | 5 | $190 |
| E.R. Squibb & Sons, L.L.C. | 10 | $184 |
| Teva Pharmaceuticals USA, Inc. | 11 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $149 |
| Lundbeck LLC | 6 | $108 |
Products named: SPRAVATO, FANAPT, HETLIOZ, REXULTI, VRAYLAR, ARISTADA, INGREZZA, COBENFY.
Industry payments across OH — which companies pay providers there.
